DDInter1562 DDInter1491
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Raloxifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) SQRDL
SQRDL {u} (Gene) is upregulated by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) downregulates {v} (Gene) IER3
IER3 {u} (Gene) is downregulated by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) SQRDL
SQRDL {u} (Gene) is regulated by {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) downregulates {v} (Gene) CCND3
CCND3 {u} (Gene) is upregulated by {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) upregulates {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Raloxifene {u} (Compound) resembles {v} (Compound) Flavoxate
Flavoxate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Raloxifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pomalidomide (Compound)
Raloxifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Raloxifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Raloxifene (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Raloxifene (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Raloxifene (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is regulated by PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Raloxifene (Compound) downregulates CCND3 (Gene) and CCND3 (Gene) is upregulated by Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Raloxifene (Compound) upregulates CYP1A1 (Gene) and CYP1A1 (Gene) regulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)
Raloxifene (Compound) resembles Flavoxate (Compound) and Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)